semaglutide news november 28 2025 FDA Approves to Reduce Kidney Disease, Cardiovascular Death Risk in Adults With Type 2 Diabetes, Chronic Kidney Disease Semaglutide – News, Research and

Recent results involving over 2000 patients indicate that a 20-week dose-escalation period followed by a 52-week treatment with three tirzepatide doses (5, 10 and 15 mg) led to striking body weight reductions in obese patients (Table 1) [44]

Given the surging popularity of obesity management drugs in recent years, the FDA put out a warning singling out compounded GLP-1s, calling them risky for patients. The agency said it had received hundreds of reports of adverse events linked to compounded semaglutide (392) and tirzepatide (215) as of Nov

Convenience For individuals averse to injections, oral semaglutide can be a more convenient and less invasive option

Your healthcare provider may adjust your dose gradually, but the weekly injection schedule remains consistent

It represents the measurable contribution of GIPR co-activation to overall metabolic effect magnitude, and it is what drives metabolic research community interest in GLP-2(Tirz) as the next-tier compound for researchers whose protocols require larger effect sizes

Second, misclassification of the cause of death is a potential concern, however, deaths from unnatural causes of death are commonly subject to autopsy and the validity of suicide is known to be high in Denmark [32]